2.

铁死亡诱导治疗相关的临床药物和化合物

Clinical drugs and compounds related to ferroptosis-inducing treatment

Classification		Drugs/Compounds	Target	Phenomena/Conclusion
GSH: glutathione; SASP: sulfasalazine; IN OPs: iron-oxide nanoparticles; LIP: labile iron pool; SQS: squalene synthase.
Existing clinical drugs		Cisplatin[30]	GSH/GPX4	Combination therapy of cisplatin with erastin showed significant synergistic effect on their anti-tumor activity[30]
		Lapatinib[31]	LIP	Lapatinib and siramesine treatment induced ferroptosis in breast cancer cells[31]
FINs	Calss Ⅰ FIN	SASP[35]	System Xc-/GSH	SASP restrained growth of NCI-H69 and LU-SCLC tissue xenografts[35]
		Sorafenib[36]		Sorafenib induced ferroptosis in NCI-H460 cells[36]
	Class Ⅱ FIN	-	GPX4	Not suitable for in vivo use due to poor pharmacokinetic[37]
	Class Ⅲ FIN	-	SQS/GPX4	Cerivastatin and simvastatin inhibit mevalonate pathway enzyme, making cells sensitive to ferroptosis [39]
	Class Ⅳ FIN	Iron compound[40, 42-44]	LIP	Iron compounds induced ferroptosis in cancer cells
		HMOX1[40, 41]
		FINO2[45, 46]
New prospects		IN OPs	LIP	Ferumoxytol has been used to inhibt the growth of lung cancer metastases[49] IN OPs with cisplatin(Ⅳ) prodrugs enhanced anticancer activity but minimized systemic toxicity [50]
		Immunotherapy	System Xc-	Immunotherapy-activated CD8+ T cells enhance lipid peroxidation in cancer cells[51]
		Radiation therapy	GSH/GPX4	IR induces ferroptosis in cancer cells and class Ⅰ, Ⅱ, Ⅲ FINs exhibit radiosensitization[55]